ABRAXANE is a microtubule inhibitor indicated for the treatment of...Locally advanced or metastatic non-small cell lung cancer (NSCLC), as first-line treatment in combination with carboplatin, in patients who are not candidates for curative surgery or radiation therapy.

Abraxane in combination with carboplatin is indicated for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy.

For patients with metastatic nonsquamous NSCLC and PS 0 and 1 who have contradictions to immunotherapy, the panel decided that the following chemotherapy regimens are "useful in certain circumstances" including 1) carboplatin with paclitaxel (or albumin-bound paclitaxel), docetaxel, etoposide, gemcitabine, or pemetrexed; all are category 1; 2) cisplatin with paclitaxel (or albumin-bound paclitaxel), docetaxel, etoposide, gemcitabine, or pemetrexed; all are category 1; 3) bevacizumab with carboplatin and either paclitaxel or pemetrexed; and 4) gemcitabine with either docetaxel or vinorelbine.